| Gillian Harrison, MD | |
|
4320 Seminary Rd, Alexandria, VA 22304-1535 | |
| (703) 504-3000 | |
| (703) 504-3388 |
| Full Name | Gillian Harrison |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 11 Years |
| Location | 4320 Seminary Rd, Alexandria, Virginia |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528405180 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 76055 (Wisconsin) | Secondary |
| 207T00000X | Neurological Surgery | 0101277030 (Virginia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Inova Alexandria Hospital | Alexandria, VA | Hospital |
| Inova Fairfax Hospital | Falls church, VA | Hospital |
| Inova Mount Vernon Hospital | Alexandria, VA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Inova Health Care Services | 2466351093 | 1725 |
| Inova Health Care Services | 2466351093 | 1725 |
News Archive
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
Experian, the leading global information services company, today announced that it has signed a definitive agreement to acquire Medical Present Value, Inc., a leading provider of revenue cycle management software, data and analytics to more than 75,000 U.S. physicians.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.
› Verified 2 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952320061 PECOS PAC ID: 2466351093 Enrollment ID: O20040102000644 |
News Archive
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
Experian, the leading global information services company, today announced that it has signed a definitive agreement to acquire Medical Present Value, Inc., a leading provider of revenue cycle management software, data and analytics to more than 75,000 U.S. physicians.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.
› Verified 2 days ago
| Entity Name | Inova Health Care Services |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1538870191 PECOS PAC ID: 2466351093 Enrollment ID: O20230206002835 |
News Archive
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
Experian, the leading global information services company, today announced that it has signed a definitive agreement to acquire Medical Present Value, Inc., a leading provider of revenue cycle management software, data and analytics to more than 75,000 U.S. physicians.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Gillian Harrison, MD 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 504-3000 | Gillian Harrison, MD 4320 Seminary Rd, Alexandria, VA 22304-1535 Ph: (703) 504-3000 |
News Archive
Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced today it has received initial prescriptions for its lead product, MuGard – an FDA-approved, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of radiotherapy and/or chemotherapy.
Experian, the leading global information services company, today announced that it has signed a definitive agreement to acquire Medical Present Value, Inc., a leading provider of revenue cycle management software, data and analytics to more than 75,000 U.S. physicians.
Inhaled insulin, taken before meals, can improve blood glucose control for people with type 2 diabetes who have not had good results with short-acting injected insulin that is taken in addition to the baseline insulin administered throughout the day and night, according to a new review of the body of published research.
To add to existing CRISPR-based nucleic acid detection protocols, a team of researchers recently established a new SARS-CoV-2 detection protocol based on their previously reported platform - CDetection (Cas12b-mediated DNA detection). They combined nucleic-acid amplification methods and sample treatment protocols with CDetection and established an integrated nucleic acid detection platform called CRISPR-assisted detection or CASdetec. CASdetec has a detection limit of 1×104 copies/mL for SARS-CoV-2 pseudovirus, without any observed cross-reactivity.
› Verified 2 days ago
Dr. Andrew A Fanous, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 1500 N Beauregard St Ste 300, Alexandria, VA 22311 Phone: 571-472-4100 Fax: 571-472-4101 |